Cargando…
Anthracycline-Related Heart Failure: Certain Knowledge and Open Questions: Where Do we Stand with Chemotherapyinduced Cardiotoxicity?
In the last decade, cardio-oncology has become a discipline on its own, with tremendous research going on to unravel the mechanisms underpinning different manifestations of cardiotoxicity caused by anticancer drugs. Although this domain is much broader than the effect of chemotherapy alone, a lot of...
Autores principales: | Robinson, Emma Louise, Azodi, Maral, Heymans, Stephane, Heggermont, Ward |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683464/ https://www.ncbi.nlm.nih.gov/pubmed/32964378 http://dx.doi.org/10.1007/s11897-020-00489-5 |
Ejemplares similares
-
The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia
por: Gatti, Milo, et al.
Publicado: (2020) -
Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer
por: Broberg, Agneta Månsson, et al.
Publicado: (2020) -
LVEF by Multigated Acquisition Scan Compared to Other Imaging Modalities in Cardio-Oncology: a Systematic Review
por: Printezi, Markella I., et al.
Publicado: (2022) -
Metabolic Aspects of Anthracycline Cardiotoxicity
por: Russo, Michele, et al.
Publicado: (2021) -
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: JACC: CardioOncology Primer
por: Henriksen, Peter A., et al.
Publicado: (2023)